This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
M ODERN CHEMOTHERAPY for malignant neoplastics disease is less than two decades old. In the early days of cortisone therapy, Richard Gubner, an internist, was interested in finding a substitute for the thenscarce cortisone for management of rheumatoid arthritis. By serendipity, he found that patients with psoriasis would respond to treatment with the anti-leukemia drug, aminopterin, administered orally. Contributions of dermatologists have included the use of aminopterin and its close relative, methotrexate, in various dosages and routes of administration in an attempt to find safe effective treatment for grave forms of psoriasis. In an article in this issue, Methotrexate for Psoriasis, a detailed catechism of possible ill-effects, both actual and theoretic, should be enough to frighten away the physician with only a casual interest in the problem. The fact that methotrexate, the successor to aminopterin, is gaining increasing use for life-ruining forms of the disease indicates the compelling need for